Fatemeh Vaghefi1 
, Farzaneh Motallebi1 , Teymoor Khosravi1 , Zainab M. Al Sudani1 , Mohaddeseh Mohsenipour1 , Arian Rahimzadeh1 , Morteza Oladnabi *2
, Farzaneh Motallebi1 , Teymoor Khosravi1 , Zainab M. Al Sudani1 , Mohaddeseh Mohsenipour1 , Arian Rahimzadeh1 , Morteza Oladnabi *2
1- Student Research Committee, Golestan University of Medical Sciences, Gorgan, Iran; Gorgan Congenital Malformations Research Center, Jorjani Clinical sciences Research Institute, Golestan University of Medical Sciences, Gorgan, Iran
2- Gorgan Congenital Malformations Research Center, Jorjani Clinical sciences Research Institute, Golestan University of Medical Sciences, Gorgan, Iran; IranIschemic Disorders Research Center, Golestan University of Medical Sciences, Gorgan, Iran; Department of Medical Genetics, School of Advanced Technologies in Medicine, Golestan University of Medical Sciences, Gorgan, Iran ,oladnabidozin@yahoo.com
2- Gorgan Congenital Malformations Research Center, Jorjani Clinical sciences Research Institute, Golestan University of Medical Sciences, Gorgan, Iran; IranIschemic Disorders Research Center, Golestan University of Medical Sciences, Gorgan, Iran; Department of Medical Genetics, School of Advanced Technologies in Medicine, Golestan University of Medical Sciences, Gorgan, Iran ,
Abstract: (194 Views)
Background: Human skin pigmentation is a complex phenotype governed by an interplay of genetic, biochemical, and physiological factors. Melanogenesis involves tightly regulated enzymatic pathways that control the balance between eumelanin and pheomelanin synthesis, ultimately determining individual skin color and influencing susceptibility to pigmentation disorders and UV-related health outcomes.
Methods: An extensive literature review was conducted to construct a comprehensive molecular framework of skin pigmentation. Key genes involved in melanogenesis, including TYR, along with regulatory microRNAs (miRNAs), were systematically analyzed. Relevant studies addressing environmental influences—particularly ultraviolet (UV) exposure—and pigmentation disorders were also evaluated.
Results: This review elucidates the central roles of melanogenic genes and miRNAs in regulating pigment production and melanocyte function. Multiple miRNAs were identified as critical modulators of melanogenesis-related pathways. Furthermore, the molecular mechanisms underlying pigmentation disorders, including oculocutaneous albinism, were characterized. Environmental factors, especially UV radiation, were shown to exert significant effects on melanogenic signaling and skin color variation.
Conclusion: Skin pigmentation is regulated through a multifaceted network of genetic, epigenetic, and environmental factors. By integrating current molecular insights, this review advances understanding of melanogenesis and associated disorders, providing a robust foundation for future research and potential therapeutic strategies targeting pigmentation-related conditions.
Methods: An extensive literature review was conducted to construct a comprehensive molecular framework of skin pigmentation. Key genes involved in melanogenesis, including TYR, along with regulatory microRNAs (miRNAs), were systematically analyzed. Relevant studies addressing environmental influences—particularly ultraviolet (UV) exposure—and pigmentation disorders were also evaluated.
Results: This review elucidates the central roles of melanogenic genes and miRNAs in regulating pigment production and melanocyte function. Multiple miRNAs were identified as critical modulators of melanogenesis-related pathways. Furthermore, the molecular mechanisms underlying pigmentation disorders, including oculocutaneous albinism, were characterized. Environmental factors, especially UV radiation, were shown to exert significant effects on melanogenic signaling and skin color variation.
Conclusion: Skin pigmentation is regulated through a multifaceted network of genetic, epigenetic, and environmental factors. By integrating current molecular insights, this review advances understanding of melanogenesis and associated disorders, providing a robust foundation for future research and potential therapeutic strategies targeting pigmentation-related conditions.
Keywords: Pigmentation, Skin Color (Skin Pigmentation), Eumelanin (eumelanin [Supplementary Concept]), Melanogenesis, Molecular Pathway
References
1. Lee A-Y. Skin pigmentation abnormalities and their possible relationship with skin aging. Int J Mol Sci. 2021;22(7):3727. [View at Publisher] [DOI] [PMID] [Google Scholar]
2. Kasraian Z, Trompezinski S, Cario-André M, Morice-Picard F, Ged C, Jullie ML, et al. Pigmentation abnormalities in nucleotide excision repair disorders: Evidence and hypotheses. Pigment Cell Melanoma Res. 2019;32(1):25-40. [View at Publisher] [DOI] [PMID] [Google Scholar]
3. Yardman‐Frank JM, Fisher DE. Skin pigmentation and its control: From ultraviolet radiation to stem cells. Exp Dermatol. 2021;30(4):560-71. [View at Publisher] [DOI] [PMID] [Google Scholar]
4. Zhou S, Zeng H, Huang J, Lei L, Tong X, Li S, et al. Epigenetic regulation of melanogenesis. Ageing Res Rev. 2021;69:101349. [View at Publisher] [DOI] [PMID] [Google Scholar]
5. Hoki Y, Araki R, Fujimori A, Ohhata T, Koseki H, Fukumura R, et al. Growth retardation and skin abnormalities of the Recql4 -deficient mouse. Human Molecular Genetics. 2003;12(18):2293-9. [View at Publisher] [DOI] [PMID] [Google Scholar]
6. Zhou Y, Zeng H-L, Wen X-Y, Jiang L, Fu C-H, Hu Y-B, et al. Selaginellin inhibits melanogenesis via the MAPK signaling pathway. J Nat Prod. 2022;85(4):838-45. [View at Publisher] [DOI] [PMID] [Google Scholar]
7. Karkoszka M, Rok J, Wrześniok D. Melanin Biopolymers in Pharmacology and Medicine-Skin Pigmentation Disorders, Implications for Drug Action, Adverse Effects and Therapy. Pharmaceuticals. 2024;17(4):521. [View at Publisher] [DOI] [PMID] [Google Scholar]
8. Goding CR, Arnheiter H. MITF-the first 25 years. Genes Dev. 2019;33(15-16):983-1007. [View at Publisher] [DOI] [PMID] [Google Scholar]
9. Anolik J, Aringer M, Bertolotti A, Boniface K, Vergier B, Mossalayi D, et al. MYO5A Gene Is a Target of MITF in Melanocytes. J Immunol. 2004;172:550e9. [View at Publisher] [Google Scholar]
10. Chamcheu JC, Siddiqui IA, Syed DN, Adhami VM, Liovic M, Mukhtar H. Keratin gene mutations in disorders of human skin and its appendages. Arch Biochem Biophys. 2011;508(2):123-37. [View at Publisher] [DOI] [PMID] [Google Scholar]
11. D'Orazio J, Jarrett S, Amaro-Ortiz A, Scott T. UV radiation and the skin. Int J Mol Sci. 2013;14(6):12222-48. [View at Publisher] [DOI] [PMID] [Google Scholar]
12. Gu W-J, Ma H-J, Zhao G, Yuan X-Y, Zhang P, Liu W, et al. Additive effect of heat on the UVB-induced tyrosinase activation and melanogenesis via ERK/p38/MITF pathway in human epidermal melanocytes. Arch Dermatol Res. 2014;306(6):583-90. [View at Publisher] [DOI] [PMID] [Google Scholar]
13. Baxter LL, Watkins‐Chow DE, Pavan WJ, Loftus SK. A curated gene list for expanding the horizons of pigmentation biology. Pigment Cell Melanoma Res. 2019;32(3):348-58. [View at Publisher] [DOI] [PMID] [Google Scholar]
14. Serre C, Busuttil V, Botto J-M. Intrinsic and extrinsic regulation of human skin melanogenesis and pigmentation. Int J Cosmet Sci. 2018;40(4):328-47. [View at Publisher] [DOI] [PMID] [Google Scholar]
15. Choi H, Shin JH, Kim ES, Park SJ, Bae I-H, Jo YK, et al. Primary cilia negatively regulate melanogenesis in melanocytes and pigmentation in a human skin model. PloS one. 2016;11(12):e0168025. [View at Publisher] [DOI] [PMID] [Google Scholar]
16. Hida T, Kamiya T, Kawakami A, Ogino J, Sohma H, Uhara H, et al. Elucidation of melanogenesis cascade for identifying pathophysiology and therapeutic approach of pigmentary disorders and melanoma. Int J Mol Sci. 2020;21(17):6129. [View at Publisher] [DOI] [PMID] [Google Scholar]
17. King RA, Pietsch J, Fryer JP, Savage S, Brott MJ, Russell-Eggitt I, et al. Tyrosinase gene mutations in oculocutaneous albinism 1 (OCA1): definition of the phenotype. Hum Genet. 2003;113(6):502-13. [View at Publisher] [DOI] [PMID] [Google Scholar]
18. Rzepka Z, Buszman E, Beberok A, Wrześniok D. From tyrosine to melanin: Signaling pathways and factors regulating melanogenesis. Postepy Hig Med Dosw (Online). 2016;70(0):695-708. [View at Publisher] [DOI] [PMID] [Google Scholar]
19. Lai X, Wichers HJ, Soler‐Lopez M, Dijkstra BW. Structure and function of human tyrosinase and tyrosinase‐related proteins. Chemistr. 2018;24(1):47-55. [View at Publisher] [DOI] [PMID] [Google Scholar]
20. Ghanem G, Fabrice J. Tyrosinase related protein 1 (TYRP1/gp75) in human cutaneous melanoma. Mol Oncol. 2011;5(2):150-5. [View at Publisher] [DOI] [PMID] [Google Scholar]
21. Rimoldi V, Straniero L, Asselta R, Mauri L, Manfredini E, Penco S, et al. Functional characterization of two novel splicing mutations in the OCA2 gene associated with oculocutaneous albinism type II. Gene. 2014;537(1):79-84. [View at Publisher] [DOI] [PMID] [Google Scholar]
22. Yang Q, Yi S, Li M, Xie B, Luo J, Wang J, et al. Genetic analyses of oculocutaneous albinism types 1 and 2 with four novel mutations. BMC Med Genet. 2019;20(1):106. [View at Publisher] [DOI] [PMID] [Google Scholar]
23. Fracasso NCA, de Andrade ES, Wiezel CEV, Andrade CCF, Zanão LR, da Silva MS, et al. Haplotypes from the SLC45A2 gene are associated with the presence of freckles and eye, hair and skin pigmentation in Brazil. Leg Med (Tokyo). 2017;25:43-51. [View at Publisher] [DOI] [PMID] [Google Scholar]
24. Suzuki T, Okamura K, Adam MP, Bick S, Mirzaa GM, Pagon RA, et al. Oculocutaneous albinism type 4. In: Adam MP, Bick S, Mirzaa GM, Pagon RA, editors.GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993–2026. updated 2017. [View at Publisher] [PMID] [Google Scholar]
25. Wei A-H, Zang D-J, Zhang Z, Liu X-Z, He X, Yang L, et al. Exome sequencing identifies SLC24A5 as a candidate gene for nonsyndromic oculocutaneous albinism. J Invest Dermatol. 2013;133(7):1834-40. [View at Publisher] [DOI] [PMID] [Google Scholar]
26. Liu F, Hamer MA, Deelen J, Lall JS, Jacobs L, van Heemst D, et al. The MC1R gene and youthful looks. Curr Biol. 2016;26(9):1213-20. [View at Publisher] [DOI] [PMID] [Google Scholar]
27. Vachtenheim J, Borovanský J. "Transcription physiology" of pigment formation in melanocytes: central role of MITF. Exp Dermatol. 2010;19(7):617-27. [View at Publisher] [DOI] [PMID] [Google Scholar]
28. Ruggiero JL, Dodds M, Freese R, Polcari IC, Maguiness S, Hook KP, et al. Cutaneous findings in Fanconi anemia. J Am Acad Dermatol. 2021;85(5):1253-8. [View at Publisher] [DOI] [PMID] [Google Scholar]
29. Mehta PA, Ebens CL. Fanconi anemia. In: Adam MP, Mirzaa GM, Pagon RA, editors. GeneReviews [Internet]. Seattle (WA): University of Washington, Seattle;(WA): University of Washington, Seattle; 1993–2021 [cited 2026 Feb 22]. [View at Publisher] [PMID] [Google Scholar]
30. Peake JD, Noguchi E. Fanconi anemia: current insights regarding epidemiology, cancer, and DNA repair. Hum Genet. 2022;141(12):1811-36. [View at Publisher] [DOI] [PMID] [Google Scholar]
31. Moreno OM, Paredes AC, Suarez‑Obando F, Rojas A. An update on Fanconi anemia: Clinical, cytogenetic and molecular approaches. Biomed Rep. 2021;15(3):74. [View at Publisher] [DOI] [PMID] [Google Scholar]
32. Ceccaldi R, Sarangi P, D'Andrea AD. The Fanconi anaemia pathway: new players and new functions. Nat Rev Mol Cell Biol. 2016;17(6):337-49. [View at Publisher] [DOI] [PMID] [Google Scholar]
33. Repczyńska A, Haus O. Genetic background and diagnosis of Fanconi anemia. Advances in Hygiene and Experimental Medicine. 2020;74:589-600. [View at Publisher] [DOI] [Google Scholar]
34. Rodríguez A, D'Andrea A. Fanconi anemia pathway. Curr Biol. 2017;27(18):R986-r8. [View at Publisher] [DOI] [PMID] [Google Scholar]
35. Helbling-Leclerc A, Garcin C, Rosselli F. Beyond DNA repair and chromosome instability-Fanconi anaemia as a cellular senescence-associated syndrome. Cell Death Differ. 2021;28(4):1159-73. [View at Publisher] [DOI] [PMID] [Google Scholar]
36. Branzei D, Foiani M. Regulation of DNA repair throughout the cell cycle. Nat Rev Mol Cell Biol. 2008;9(4):297-308. [View at Publisher] [DOI] [PMID] [Google Scholar]
37. Barnum KJ, O'Connell MJ. Cell cycle regulation by checkpoints. Methods Mol Biol. 2014:1170:29-40. [View at Publisher] [DOI] [PMID] [Google Scholar]
38. Phan LM, Rezaeian A-H. ATM: Main Features, Signaling Pathways, and Its Diverse Roles in DNA Damage Response, Tumor Suppression, and Cancer Development. Genes. 2021;12(6):845. [View at Publisher] [DOI] [PMID] [Google Scholar]
39. Elkoshi N, Parikh S, Malcov-Brog H, Parikh R, Manich P, Netti F, et al. Ataxia Telangiectasia Mutated Signaling Delays Skin Pigmentation upon UV Exposure by Mediating MITF Function toward DNA Repair Mode. J Invest Dermatol. 2023;143(12):2494-506.e4. [View at Publisher] [DOI] [PMID] [Google Scholar]
40. Wang Q, Lv H, Lv W, Shi M, Zhang M, Luan M, et al. Genome-wide haplotype association study identifies BLM as a risk gene for prostate cancer in Chinese population. Tumour Biol. 2015;36:2703-7. [View at Publisher] [DOI] [PMID] [Google Scholar]
41. Bythell-Douglas R, Deans AJ. A structural guide to the Bloom syndrome complex. Structure. 2021;29(2):99-113. [View at Publisher] [DOI] [PMID] [Google Scholar]
42. Cunniff C, Bassetti JA, Ellis NA. Bloom's syndrome: clinical spectrum, molecular pathogenesis, and cancer predisposition. Mol Syndromol. 2017;8(1):4-23. [View at Publisher] [DOI] [PMID] [Google Scholar]
43. Park Ji, Lee HY, Lee JE, Myung Ch, Hwang JS. Inhibitory effect of 2-methyl-naphtho[1,2,3-de]quinolin-8-one on melanosome transport and skin pigmentation. Sci Rep. 2016:6:29189. [View at Publisher] [DOI] [PMID] [Google Scholar]
44. Rybanská I, Gurský J, Fašková M, Salazar EP, Kimlíčková-Polakovičová E, Kleibl K, et al. Newly identified CHO ERCC3/XPB mutations and phenotype characterization. Mutagenesis. 2010;25(2):179-85. [View at Publisher] [DOI] [PMID] [Google Scholar]
45. Zhu M-L, Wang M, Cao Z-G, He J, Shi T-Y, Xia K-Q, et al. Association between the ERCC5 Asp1104His polymorphism and cancer risk: a meta-analysis. PLoS One. 2012;7(7):e36293. [View at Publisher] [DOI] [PMID] [Google Scholar]
46. Bogliolo M, Schuster B, Stoepker C, Derkunt B, Su Y, Raams A, et al. Mutations in ERCC4, encoding the DNA-repair endonuclease XPF, cause Fanconi anemia. Am J Hum Genet. 2013;92(5):800-6. [View at Publisher] [DOI] [PMID] [Google Scholar]
47. Manandhar M, Boulware KS, Wood RD. The ERCC1 and ERCC4 (XPF) genes and gene products. Gene. 2015;569(2):153-61. [View at Publisher] [DOI] [PMID] [Google Scholar]
48. Li M, Chen R, Ji B, Fan C, Wang G, Yue C, et al. Role of ERCC5 polymorphisms in non‑small cell lung cancer risk and responsiveness/toxicity to cisplatin‑based chemotherapy in the Chinese population. Oncol Rep. 2021;45(3):1295-305. [View at Publisher] [DOI] [PMID] [Google Scholar]
49. Bronner CE, Baker SM, Morrison PT, Warren G, Smith LG, Lescoe MK, et al. Mutation in the DNA mismatch repair gene homologue hMLH1 is associated with hereditary non-polyposis colon cancer. Nature. 1994;368(6468):258-61. [View at Publisher] [DOI] [PMID] [Google Scholar]
50. van der Klift HM, Mensenkamp AR, Drost M, Bik EC, Vos YJ, Gille HJ, et al. Comprehensive Mutation Analysis of PMS2 in a Large Cohort of Probands Suspected of Lynch Syndrome or Constitutional Mismatch Repair Deficiency Syndrome. Hum Mutat. 2016;37(11):1162-79. [View at Publisher] [DOI] [PMID] [Google Scholar]
51. Bianchi F, Maccaroni E, Belvederesi L, Brugiati C, Giampieri R, Bini F, et al. A germline missense mutation in exon 3 of the MSH2 gene in a Lynch syndrome family: correlation with phenotype and localization assay. Fam Cancer. 2018;17(2):215-24. [View at Publisher] [DOI] [PMID] [Google Scholar]
52. Sample A, He Y-Y. Mechanisms and prevention of UV-induced melanoma. Photodermatol Photoimmunol Photomed. 2018;34(1):13-24. [View at Publisher] [DOI] [PMID] [Google Scholar]
53. Luong TT, Bernstein KA. Role and Regulation of the RECQL4 Family during Genomic Integrity Maintenance. Genes. 2021;12(12):1919. [View at Publisher] [DOI] [PMID] [Google Scholar]
54. Kitao S, Shimamoto A, Goto M, Miller RW, Smithson WA, Lindor NM, et al. Mutations in RECQL4 cause a subset of cases of Rothmund-Thomson syndrome. Nat Genet. 1999;22(1):82-4. [View at Publisher] [DOI] [PMID] [Google Scholar]
55. Luong TT, Bernstein KA. Role and Regulation of the RECQL4 Family during Genomic Integrity Maintenance. Genes (Basel). 2021;12(12):1919. [View at Publisher] [DOI] [PMID] [Google Scholar]
56. Yusufzai T, Kadonaga JT. HARP is an ATP-driven annealing helicase. Science. 2008;322(5902):748-50. [View at Publisher] [DOI] [PMID] [Google Scholar]
57. Baradaran-Heravi A, Cho KS, Tolhuis B, Sanyal M, Morozova O, Morimoto M, et al. Penetrance of biallelic SMARCAL1 mutations is associated with environmental and genetic disturbances of gene expression. Hum Mol Genet. 2012;21(11):2572-87. [View at Publisher] [DOI] [PMID] [Google Scholar]
58. Murray HC, Maltby VE, Smith DW, Bowden NA. Nucleotide excision repair deficiency in melanoma in response to UVA. Exp Hematol Oncol. 2016:5:6. [View at Publisher] [DOI] [PMID] [Google Scholar]
59. Miller KL, Karagas MR, Kraft P, Hunter DJ, Catalano PJ, Byler SH, et al. XPA, haplotypes, and risk of basal and squamous cell carcinoma. Carcinogenesis. 2006;27(8):1670-5. [View at Publisher] [DOI] [PMID] [Google Scholar]
60. Wang B, Xu Q, Yang H-W, Sun L-P, Yuan Y. The association of six polymorphisms of five genes involved in three steps of nucleotide excision repair pathways with hepatocellular cancer risk. Oncotarget. 2016;7(15):20357-67. [View at Publisher] [DOI] [PMID] [Google Scholar]
61. Molinari F, Frattini M. Functions and Regulation of the PTEN Gene in Colorectal Cancer. Front Oncol. 2014:3:326. [View at Publisher] [DOI] [PMID] [Google Scholar]
62. Cao J, Wan L, Hacker E, Dai X, Lenna S, Jimenez-Cervantes C, et al. MC1R is a potent regulator of PTEN after UV exposure in melanocytes. Mol Cell. 2013;51(4):409-22. [View at Publisher] [DOI] [PMID] [Google Scholar]
63. Ming M, Feng L, Shea CR, Soltani K, Zhao B, Han W, et al. PTEN positively regulates UVB-induced DNA damage repair. Cancer Res. 2011;71(15):5287-95. [View at Publisher] [DOI] [PMID] [Google Scholar]
64. Chiarelli N, Carini G, Zoppi N, Ritelli M, Colombi M. Molecular insights in the pathogenesis of classical Ehlers-Danlos syndrome from transcriptome-wide expression profiling of patients' skin fibroblasts. PLoS One. 2019;14(2):e0211647. [View at Publisher] [DOI] [PMID] [Google Scholar]
65. Luo Y, Bai R, Wang Z, Zhu X, Xing J, Li X. STAR mutations causing non‑classical lipoid adrenal hyperplasia manifested as familial glucocorticoid deficiency. Mol Med Rep. 2020;22(2):681-6. [View at Publisher] [DOI] [PMID] [Google Scholar]
66. Meimaridou E, Hughes CR, Kowalczyk J, Guasti L, Chapple JP, King PJ, et al. Familial glucocorticoid deficiency: New genes and mechanisms. Mol Cell Endocrinol. 2013;371(1-2):195-200. [View at Publisher] [DOI] [PMID] [Google Scholar]
67. Daniell J, Plazzer J-P, Perera A, Macrae F. An exploration of genotype-phenotype link between Peutz-Jeghers syndrome and STK11: a review. Fam Cancer. 2018;17(3):421-7. [View at Publisher] [DOI] [PMID] [Google Scholar]
68. Jelsig AM, Bertelsen B, Forss I, Karstensen JG. Two cases of somatic STK11 mosaicism in Danish patients with Peutz-Jeghers syndrome. Fam Cancer. 2021;20(1):55-9. [View at Publisher] [DOI] [PMID] [Google Scholar]
69. Stefanoudakis D, Frountzas M, Schizas D, Michalopoulos NV, Drakaki A, Toutouzas KG. Significance of TP53, CDKN2A, SMAD4 and KRAS in Pancreatic Cancer. Curr Issues Mol Biol. 2024;46(4):2827-44. [View at Publisher] [DOI] [PMID] [Google Scholar]
70. Danishevich A, Bilyalov A, Nikolaev S, Khalikov N, Isaeva D, Levina Y, et al. CDKN2A Gene Mutations: Implications for Hereditary Cancer Syndromes. Biomedicines. 2023;11(12):3343. [View at Publisher] [DOI] [PMID] [Google Scholar]
71. Morrison DK. MAP kinase pathways. Cold Spring Harb Perspect Biol. 2012;4(11):a011254. [View at Publisher] [DOI] [PMID] [Google Scholar]
72. Enkhtaivan E, Lee CH. Role of amine neurotransmitters and their receptors in skin pigmentation: therapeutic implication. Int J Mol Sci. 2021;22(15):8071. [View at Publisher] [DOI] [PMID] [Google Scholar]
73. Den Hoed M, Eijgelsheim M, Esko T, Brundel BJ, Peal DS, Evans DM, et al. Identification of heart rate-associated loci and their effects on cardiac conduction and rhythm disorders. Nat Genet. 2013;45(6):621-31. [View at Publisher] [DOI] [PMID] [Google Scholar]
74. Sinkala M, Nkhoma P, Mulder N, Martin DP. Integrated molecular characterisation of the MAPK pathways in human cancers reveals pharmacologically vulnerable mutations and gene dependencies. Commun Biol. 2021;4(1):9. [View at Publisher] [DOI] [PMID] [Google Scholar]
75. Shuaib A, Hartwell A, Kiss-Toth E, Holcombe M. Multi-compartmentalisation in the MAPK signalling pathway contributes to the emergence of oscillatory behaviour and to ultrasensitivity. PloS One. 2016;11(5):e0156139. [View at Publisher] [DOI] [PMID] [Google Scholar]
76. Cheung HW, Cowley GS, Weir BA, Boehm JS, Rusin S, Scott JA, et al. Systematic investigation of genetic vulnerabilities across cancer cell lines reveals lineage-specific dependencies in ovarian cancer. Proc Natl Acad Sci U S A. 2011;108(30):12372-7. [View at Publisher] [DOI] [PMID] [Google Scholar]
77. Kim J-M, Yang Y-S, Park KH, Oh H, Greenblatt MB, Shim J-H. The ERK MAPK pathway is essential for skeletal development and homeostasis. Int J Mol Sci. 2019;20(8):1803. [View at Publisher] [DOI] [PMID] [Google Scholar]
78. Fu C, Chen J, Lu J, Yi L, Tong X, Kang L, et al. Roles of inflammation factors in melanogenesis. Mol Med Rep. 2020;21(3):1421-30. [View at Publisher] [DOI] [PMID] [Google Scholar]
79. Kannengiesser C, Spatz A, Michiels S, Eychène A, Dessen P, Lazar V, et al. Gene expression signature associated with BRAF mutations in human primary cutaneous melanomas. Mol Oncol. 2008;1(4):425-30. [View at Publisher] [DOI] [PMID] [Google Scholar]
80. Mo X, Preston S, Zaidi MR. Macroenvironment-gene-microenvironment interactions in ultraviolet radiation-induced melanomagenesis. Adv Cancer Res. 2019;144:1-54. [View at Publisher] [DOI] [Google Scholar]
81. Sarin KY, McNiff JM, Kwok S, Kim J, Khavari PA. Activating HRAS mutation in nevus spilus. J Invest Dermatol. 2014;134(6):1766-8. [View at Publisher] [DOI] [PMID] [Google Scholar]
82. Santoriello C, Gennaro E, Anelli V, Distel M, Kelly A, Köster RW, et al. Kita driven expression of oncogenic HRAS leads to early onset and highly penetrant melanoma in zebrafish. PloS One. 2010;5(12):e15170. [View at Publisher] [DOI] [PMID] [Google Scholar]
83. Saravanaperumal SA, Pallotti S, Pediconi D, Renieri C, La Terza A. Exon-1 skipping and intron-1 retaining by alternative splicing of the c-KIT gene encodes a novel splice variant in the skin of Merino sheep (Ovis aries). Mol Biol Rep. 2021;48(5):4987-94. [View at Publisher] [DOI] [PMID] [Google Scholar]
84. Miettinen M, Lasota J. KIT (CD117): a review on expression in normal and neoplastic tissues, and mutations and their clinicopathologic correlation. Appl Immunohistochem Mol Morphol. 2005;13(3):205-20. [View at Publisher] [DOI] [PMID] [Google Scholar]
85. Atit RP, Mitchell K, Nguyen L, Warshawsky D, Ratner N. The neurofibromatosis type 1 (Nf1) tumor suppressor is a modifier of carcinogen-induced pigmentation and papilloma formation in C57BL/6 mice. J Invest Dermatol. 2000;114(6):1093-100. [View at Publisher] [DOI] [PMID] [Google Scholar]
86. Lemos MC, Thakker RV. Multiple endocrine neoplasia type 1 (MEN1): analysis of 1336 mutations reported in the first decade following identification of the gene. Hum Mutat. 2008;29(1):22-32. [View at Publisher] [DOI] [PMID] [Google Scholar]
87. Heppner C, Bilimoria KY, Agarwal SK, Kester M, Whitty LJ, Guru SC, et al. The tumor suppressor protein menin interacts with NF-κB proteins and inhibits NF-κB-mediated transactivation. Oncogene. 2001;20(36):4917-25. [View at Publisher] [DOI] [PMID] [Google Scholar]
88. Horn S, Figl A, Rachakonda PS, Fischer C, Sucker A, Gast A, et al. TERT promoter mutations in familial and sporadic melanoma. Science. 2013;339(6122):959-61. [View at Publisher] [DOI] [PMID] [Google Scholar]
89. Freda PU, Chung WK, Matsuoka N, Walsh JE, Kanibir MN, Kleinman G, et al. Analysis of GNAS mutations in 60 growth hormone secreting pituitary tumors: correlation with clinical and pathological characteristics and surgical outcome based on highly sensitive GH and IGF-I criteria for remission. Pituitary. 2007;10(3):275-82. [View at Publisher] [DOI] [PMID] [Google Scholar]
90. Legius E, Marchuk DA, Collins FS, Glover TW. Somatic deletion of the neurofibromatosis type 1 gene in a neurofibrosarcoma supports a tumour suppressor gene hypothesis. Nat Genet. 1993;3(2):122-6. [View at Publisher] [DOI] [PMID] [Google Scholar]
91. Khosravi T, Oladnabi M. The role of miRNAs and lncRNAs in neurofibromatosis type 1. J Cell Biochem. 2023;124(1):17-30. [View at Publisher] [DOI] [PMID] [Google Scholar]
92. Wolf Horrell EM, Boulanger MC, D'Orazio JA. Melanocortin 1 receptor: structure, function, and regulation. Front Genet. 2016:7:95. [View at Publisher] [DOI] [PMID] [Google Scholar]
93. Gantz I, Fong TM. The melanocortin system. Am J Physiol Endocrinol Metab. 2003;284(3):E468-E74. [View at Publisher] [DOI] [PMID] [Google Scholar]
94. Rodríguez CI, Setaluri V. Cyclic AMP (cAMP) signaling in melanocytes and melanoma. Arch Biochem Biophys. 2014;563:22-7. [View at Publisher] [DOI] [PMID] [Google Scholar]
95. Kadekaro AL, Leachman S, Kavanagh RJ, Swope V, Cassidy P, Supp D, et al. Melanocortin 1 receptor genotype: an important determinant of the damage response of melanocytes to ultraviolet radiation. FASEB J. 2010;24(10):3850-60. [View at Publisher] [DOI] [PMID] [Google Scholar]
96. Nordlund JJ. The melanocyte and the epidermal melanin unit: an expanded concept. Dermatol Clin. 2007;25(3):271-81. [View at Publisher] [DOI] [PMID] [Google Scholar]
97. Hearing VJ. Determination of melanin synthetic pathways. J Invest Dermatol. 2011;131(E1):E8-E11. [View at Publisher] [DOI] [PMID] [Google Scholar]
98. Hushcha Y, Blo I, Oton-Gonzalez L, Mauro GD, Martini F, Tognon M, et al. microRNAs in the Regulation of Melanogenesis. Int J Mol Sci. 2021;22(11):6104. [View at Publisher] [DOI] [PMID] [Google Scholar]
99. O'Brien J, Hayder H, Zayed Y, Peng C. Overview of microRNA biogenesis, mechanisms of actions, and circulation. Front Endocrinol (Lausanne). 2018:9:402. [View at Publisher] [DOI] [PMID] [Google Scholar]
100. Mione M, Bosserhoff A. MicroRNAs in melanocyte and melanoma biology. Pigment Cell Melanoma Res. 2015;28(3):340-54. [View at Publisher] [DOI] [PMID] [Google Scholar]
101. Kim K-H, Bin B-H, Kim J, Dong SE, Park PJ, Choi H, et al. Novel inhibitory function of miR‐125b in melanogenesis. Pigment Cell Melanoma Res. 2014;27(1):140-4. [View at Publisher] [DOI] [PMID] [Google Scholar]
102. Šahmatova L, Tankov S, Prans E, Aab A, Hermann H, Reemann P, et al. MicroRNA-155 is Dysregulated in the Skin of Patients with Vitiligo and Inhibits Melanogenesis-associated Genes in Melanocytes and Keratinocytes. Acta Derm Venereol. 2016;96(6):742-7. [View at Publisher] [DOI] [PMID] [Google Scholar]
103. Ji K, Zhang P, Zhang J, Fan R, Liu Y, Yang S, et al. MicroRNA 143‐5p regulates alpaca melanocyte migration, proliferation and melanogenesis. Exp Dermatol. 2018;27(2):166-71. [View at Publisher] [DOI] [PMID] [Google Scholar]
104. Dynoodt P, Mestdagh P, Van Peer G, Vandesompele J, Goossens K, Peelman LJ, et al. Identification of miR-145 as a key regulator of the pigmentary process. J Invest Dermatol. 2013;133(1):201-9. [View at Publisher] [DOI] [PMID] [Google Scholar]
105. Itoh T, Fukatani K, Nakashima A, Suzuki K. MicroRNA-141-3p and microRNA-200a-3p regulate α-melanocyte stimulating hormone-stimulated melanogenesis by directly targeting microphthalmia-associated transcription factor. Sci Rep. 2020;10(1):2149. [View at Publisher] [DOI] [PMID] [Google Scholar]
106. Yang Y, Wei X, Bai J, Huang M, Hao T, Hao Y, et al. MicroRNA-340 is involved in ultraviolet B-induced pigmentation by regulating the MITF/TYRP1 axis. J Int Med Res. 2020;48(11):0300060520971510. [View at Publisher] [DOI] [PMID] [Google Scholar]
107. Shi Q, Zhang W, Guo S, Jian Z, Li S, Li K, et al. Oxidative stress-induced overexpression of miR-25: the mechanism underlying the degeneration of melanocytes in vitiligo. Cell Death Differ. 2016;23(3):496-508. [View at Publisher] [DOI] [PMID] [Google Scholar]
108. Jiang S, Yu X, Dong C. MiR-137 affects melanin synthesis in mouse melanocyte by repressing the expression of c-Kit and Tyrp2 in SCF/c-Kit signaling pathway. Biosci Biotechnol Biochem. 2016;80(11):2115-21. [View at Publisher] [DOI] [PMID] [Google Scholar]
109. Kim K-H, Lee TR, Cho E-G. SH3BP4, a novel pigmentation gene, is inversely regulated by miR-125b and MITF. Exp Mol Med. 2017;49(8):e367. [View at Publisher] [DOI] [PMID] [Google Scholar]
110. Kim K-H, Bin B-H, Kim J, Dong SE, Park PJ, Choi H, et al. Novel inhibitory function of miR-125b in melanogenesis. Pigment Cell Melanoma Res. 2014;27(1):140-4. [View at Publisher] [DOI] [PMID] [Google Scholar]
111. Dong Z, Luo M, Wang L, Yin H, Zhu W, Fu J. MicroRNA-206 Regulation of Skin Pigmentation in Koi Carp (Cyprinus carpio L.). Front Genet. 2020;11:47. [View at Publisher] [DOI] [PMID] [Google Scholar]
112. Hushcha Y, Blo I, Oton-Gonzalez L, Mauro GD, Martini F, Tognon M, et al. microRNAs in the Regulation of Melanogenesis. Int J Mol Sci. 2021;22(11):6104. [View at Publisher] [DOI] [PMID] [Google Scholar]
113. Maddodi N, Jayanthy A, Setaluri V. Shining light on skin pigmentation: the darker and the brighter side of effects of UV radiation. Photochem Photobiol. 2012;88(5):1075-82. [View at Publisher] [DOI] [PMID] [Google Scholar]
114. Solano F. Photoprotection and skin pigmentation: Melanin-related molecules and some other new agents obtained from natural sources. Molecules. 2020;25(7):1537. [View at Publisher] [DOI] [PMID] [Google Scholar]
115. Olad Nabi M, Mirabzadeh A, Feizzadeh G, Khorram Khorshid H, Karimlou M, Zarif Yeganeh M, et al. Novel mutations in the calreticulin gene core promoter and coding sequence in schizoaffective disorder. Am J Med Genet B Neuropsychiatr Genet. 2010;153(2):706-9. [View at Publisher] [DOI] [PMID] [Google Scholar]
116. Petrescu SM. Do calnexin and calreticulin have a role in melanin formation? IUBMB life. 2005;57(6):455-7. [View at Publisher] [DOI] [PMID] [Google Scholar]
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0).
